Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from February 28, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on May 29, 2026.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted
$1,051.99 Published $1,157.19 Target $1,105.00 Window close $1,149.10 Peak
$1,030.00 – $1,065.00Entry zone — fair-value band
$1,051.99Published — price the day we called it
$1,157.19Target — the price the thesis aimed for
$1,149.10Peak — highest point inside the window, not a realized return
$1,105.00Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price
$1,149.10
peak on May 28, 2026 — not a realized return
Peak gain
+9.2%
peak, from the publication price
Window close
$1,105.00
end-of-window price, context only
Days to target
—
Window
February 28, 2026 – May 29, 2026

The thesis — published February 28, 2026

Predicted growth
+10%
over the measurement window
Target price
$1,157.19
the price the thesis aimed for
Entry zone
$1,030.00 – $1,065.00
the fair-value band we waited for
Price at publication
$1,051.99
published February 28, 2026
Confidence
81%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Eli Lilly is getting attention because a promising oral obesity drug result and active regulatory filings keep the obesity business in the spotlight. That can encourage big investors to buy when it dips. The overall trend is positive, but the stock can move quickly on competitor news, so prefer buying small drops rather than chasing big rallies.

Primary drivers

  • Positive oral GLP-1 news keeps demand high
  • Market sees Lilly as a safe healthcare leader in choppy times
  • Defined dip-buy plan helps limit risk
  • Regular filings and trials keep headlines coming

How it played out

LLY: thesis nearly reached target but did not get there

Lyra published LLY at $1051.99 on 2026-02-28 with a 10% expected gain and a $1157.19 target. The thesis pointed to oral GLP-1 news, obesity-related demand, a view of Lilly as a safer healthcare leader in choppy markets, a dip-buy plan, and regular filings and trials.

Inside the 2026-02-28 to 2026-05-29 window, LLY rose to $1149.10 on 2026-05-28, a 9.2% peak gain. It stayed below the target. The stock ended at $1105. The thesis mostly played out, but the published target was missed.

What happened during the window

On 2026-04-01, the FDA approved Lilly's oral weight-loss pill Foundayo, according to The Guardian. On 2026-04-30, MarketWatch reported Lilly's first-quarter results, including $12.9 billion in GLP-1 drug sales and a raised 2026 revenue forecast.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals